Therefore, blocking the interaction between S100A8 and TLR4 by targeting S100A8 residues involved in TLR4 binding could represent a new option for the treatment of ALI and other inflammatory lung diseases. This evidence concerns the gene TLR4 and acute respiratory distress syndrome.